LB制药
LBRX
36.74
+0.05
+0.14%
LB制药
US · LBRX
#3180 按市值排名
上市于 2025
36.74
+0.05
+0.14%
实时 - 追踪5344个代码 - 心跳于493秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
减持
- 机构持股总比例下降了12.6个百分点。
机构持股
- 机构持股比例
- 100.50% -12.64pp
- 机构数量
- 146
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Hedge Fund34.31%
VC/PE Fund34.26%
Mutual Fund27.99%
Public Company2.73%
Individual/Insider0.73%
Sovereign Wealth Fund0.50%
Private Company0.48%
Insurance Company0.14%
主要股东 截至 2026-06-30
Deep Track Capital, LP
10.39% · 3.35M 股
BlackRock
8.48% · 2.73M 股
RA Capital Management, L.P.
6.85% · 2.21M 股
Trails Edge Capital Partners, LP
4.72% · 1.52M 股
Commodore Capital LP
4.65% · 1.50M 股
J.P. Morgan Asset Management, Inc.
4.53% · 1.46M 股
TCG Crossover Management, LLC
4.49% · 1.45M 股
Caligan Partners, LP
4.46% · 1.44M 股
Pontifax Venture Capital
4.38% · 1.41M 股
Spruce Street Capital LP
4.27% · 1.38M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 26次买入 · 9次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Deep Track Capital, LP | -- | 10.39% |
| Heather Turner | Chief Executive Officer | 0.21% |
| Zachary Prensky | -- | 0.19% |
| Scott Garland | Independent Chairman of Board | 0.04% |
| Marc Panoff | Officer | 0.03% |
| Gad Soffer | Chief Business Officer | 0.03% |
| Anna Eramo | Chief Medical Officer | 0.01% |
| Robert Richard Ruffolo | Independent Director | 0.01% |
| David Kroin | -- | -- |
| Pontifax Venture Capital | -- | -- |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-07-29 | David Kroin | -- | Open Market Derivative Acquisiti | +286,205 | $0.00 |
| 2026-06-08 | Zachary Prensky | -- | Intent to Sell (Form 144) | -16,500 | $29.49 |
| 2026-06-02 | Robert Richard Ruffolo | Independent Director | Other Derivative Acquisition | +10,000 | $27.95 |
| 2026-06-02 | Ran Nussbaum | Independent Director | Other Derivative Acquisition | +10,000 | $27.95 |
| 2026-06-02 | William Kane | Former Independent Director | Other Derivative Acquisition | +10,000 | $27.95 |
| 2026-06-02 | Scott Garland | Independent Chairman of Board | Other Derivative Acquisition | +10,000 | $27.95 |
| 2026-06-02 | Rebecca Luse | Independent Director | Other Derivative Acquisition | +10,000 | $27.95 |
| 2026-06-02 | Rekha Hemrajani | Former Independent Director | Other Derivative Acquisition | +10,000 | $27.95 |
| 2026-06-02 | Robert Lenz | Director | Other Derivative Acquisition | +12,500 | $27.95 |
| 2026-03-05 | Robert Lenz | Director | Other Derivative Acquisition | +20,000 | $23.78 |
| 2026-02-05 | Deep Track Capital, LP | -- | Open Market Derivative Acquisiti | +472,369 | $0.00 |
| 2025-12-09 | Kaya Pai Panandiker | Chief Commercial Officer | Other Derivative Acquisition | +195,000 | $21.36 |
| 2025-09-11 | Pontifax Venture Capital | -- | Private Acquisition | +1,000,000 | $15.00 |
| 2025-09-11 | Pontifax Venture Capital | -- | Derivative Exercise and Retained | +411,681 | -- |
| 2025-09-11 | Deep Track Capital, LP | -- | Private Acquisition | +2,666,666 | $15.00 |
| 2025-09-11 | Deep Track Capital, LP | -- | Derivative Exercise and Retained | +686,138 | -- |
| 2025-09-11 | Deep Track Capital, LP | -- | Initial Statement of Beneficial | 0 | -- |
| 2025-09-09 | Robert Richard Ruffolo | Independent Director | Derivative Sale to Issuer | -13,266 | -- |
| 2025-09-09 | Robert Richard Ruffolo | Independent Director | Other Derivative Acquisition | +35,715 | $15.00 |
| 2025-09-09 | Robert Richard Ruffolo | Independent Director | Initial Statement of Beneficial | 0 | -- |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
LB制药 讨论区 0 条评论